• Overview

    Research OverviewSince ACCRF was founded in December 2005, a vibrant community of researchers, supported by patients, has sprung into action. Investigators have worked together across academia, government agencies and private industry to move forward the various projects within the Research Agenda. A collaborative spirit has been evident as specimens, models and data have been shared in a manner seldom seen in scientific research. The results have been remarkable as shown in the table below:

    ACC Research Progress Since ACCRF’s Inception

    2005 2015
    Research Network Few investigators, modest interest in ACC 50 grantees with vibrant interactions and sharing of materials and data
    Biobanking Limited Repositories with hundreds of frozen tumor specimens
    Cell Lines Multiple invalid models Misidentifications discovered; valid models in development
    Animal Models None 20+ mouse xenografts developed; progress in transgenic models
    Genomics Sporadic reports of translocations Discovery of MYB rearrangements and upregulation
    Identification of additional molecular targets with potential therapies: FGFR, NOTCH, IGF-1R, HDAC, TRK
    Preclinical Drug Screens None in valid models Open xenograft platform for academia and industry
    Strong relationships with biopharmaceutical companies
    30 approved and 50 novel compounds screened in xenografts
    Mobilizing Patients Limited Tissue donations, clinical trial accrual and over $12 million in donations
    NIH Commitments Negligible Over $25 million for salivary gland tumor research (NIDCR)
    Clinical Trials Few, small & haphazard Multiple science-driven trials with improved designs, enrollment, data quality and patient outcomes
    Download ACC Research Progress Since ACCRF’s Inception

    The ultimate goal of a cure has not yet been reached. However, basic and translational research projects are unearthing important molecular targets that are responsible for the development of ACC. And the rational pursuit of those molecular targets is raising the quality and promise of clinical trials for ACC patients. Momentum is clearly building. With the continued support of the ACC patient community, ACC researchers will continue to make enormous strides.